Cargando…
Risk–efficacy balance of ulipristal acetate compared to surgical alternatives
AIMS: Uterine fibroids are benign tumours that cause various complaints. These complaints may significantly compromise quality of life, necessitating a clinical intervention in 25–50% of the affected women. Hysterectomy, myomectomy or embolization may offer symptomatic relief, but are costly, includ...
Autores principales: | Middelkoop, Mei‐An, Bet, Pierre M., Drenth, Joost P.H., Huirne, Judith A.F., Hehenkamp, Wouter J.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359338/ https://www.ncbi.nlm.nih.gov/pubmed/33341097 http://dx.doi.org/10.1111/bcp.14708 |
Ejemplares similares
-
Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids
por: Middelkoop, Mei-An, et al.
Publicado: (2022) -
Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis
por: de Milliano, Inge, et al.
Publicado: (2017) -
Ulipristal Acetate in Adenomyosis
por: Gonçalves-Henriques, Manuel, et al.
Publicado: (2022) -
Ulipristal acetate vs gonadotropin‐releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Short‐term results of a double‐blind randomized controlled trial
por: de Milliano, Inge, et al.
Publicado: (2019) -
Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France
por: Fernandez, Hervé, et al.
Publicado: (2017)